Selected research
Industry Growth & Trends
Global RNA-Targeted Small Molecules Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global RNA-Targeted Small Molecules market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for RNA-Targeted Small Molecules is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for RNA-Targeted Small Molecules is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for RNA-Targeted Small Molecules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the RNA-Targeted Small Molecules market include Twentyeight-Seven Therapeutics, STORM Therapeutics, Skyhawk Therapeutics, Ribometrix, H3 Biomedicine, Gotham Therapeutics, Expansion Therapeutics, Epics Therapeutics and Arrakis Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global RNA-Targeted Small Molecules market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The RNA-Targeted Small Molecules market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global RNA-Targeted Small Molecules market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to RNA-Targeted Small Molecules.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global RNA-Targeted Small Molecules market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
RNA-Targeted Small Molecules Market by Company
Twentyeight-Seven Therapeutics
STORM Therapeutics
Skyhawk Therapeutics
Ribometrix
H3 Biomedicine
Gotham Therapeutics
Expansion Therapeutics
Epics Therapeutics
Arrakis Pharmaceuticals
Anima Biotech Inc.
Accent Therapeutics
RNA-Targeted Small Molecules Segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Indirect RNA Targeting - Epitranscriptomics
Direct RNA Targeting
RNA-Targeted Small Molecules Segment by Application
Laboratories
Hospitals
Phamacy
RNA-Targeted Small Molecules Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecules and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecules.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of RNA-Targeted Small Molecules companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA Translation Regulation
- RNA Splicing Modification
- Indirect RNA Targeting - Epitranscriptomics
- Direct RNA Targeting
Applications
- Laboratories
- Hospitals
- Phamacy
Companies covered
- Twentyeight-Seven Therapeutics
- STORM Therapeutics
- Skyhawk Therapeutics
- Ribometrix
- H3 Biomedicine
- Gotham Therapeutics
- Expansion Therapeutics
- Epics Therapeutics
- Arrakis Pharmaceuticals
- Anima Biotech Inc.
- Accent Therapeutics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global RNA-Targeted Small Molecules Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global RNA-Targeted Small Molecules Market Size by Region (2021-2032)
- 1.4.1 Global RNA-Targeted Small Molecules Market Size by Region (2021-2026)
- 1.4.2 Global RNA-Targeted Small Molecules Market Size by Region (2027-2032)
- 1.5 Key Regions RNA-Targeted Small Molecules Market Size (2021-2032)
- 1.5.1 North America RNA-Targeted Small Molecules Market Size Growth Rate (2021-2032)
- 1.5.2 Europe RNA-Targeted Small Molecules Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific RNA-Targeted Small Molecules Market Size Growth Rate (2021-2032)
- 1.5.4 South America RNA-Targeted Small Molecules Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa RNA-Targeted Small Molecules Market Size Growth Rate (2021-2032)
2 RNA-Targeted Small Molecules Market by Type
- 2.1 Type Introduction
- 2.1.1 mRNA Translation Regulation
- 2.1.2 RNA Splicing Modification
- 2.1.3 Indirect RNA Targeting - Epitranscriptomics
- 2.1.4 Direct RNA Targeting
- 2.2 Global RNA-Targeted Small Molecules Market Size by Type
- 2.2.1 Global RNA-Targeted Small Molecules Market Size Overview by Type (2021-2032)
- 2.2.2 Global RNA-Targeted Small Molecules Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global RNA-Targeted Small Molecules Market Size Forecasted by Type (2027-2032)
- 2.3 Global RNA-Targeted Small Molecules Market Size by Regions
- 2.3.1 North America RNA-Targeted Small Molecules Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe RNA-Targeted Small Molecules Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific RNA-Targeted Small Molecules Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America RNA-Targeted Small Molecules Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa RNA-Targeted Small Molecules Market Size Breakdown by Type (2021-2026)
3 RNA-Targeted Small Molecules Market by Application
- 3.1 Type Introduction
- 3.1.1 Laboratories
- 3.1.2 Hospitals
- 3.1.3 Phamacy
- 3.2 Global RNA-Targeted Small Molecules Market Size by Application
- 3.2.1 Global RNA-Targeted Small Molecules Market Size Overview by Application (2021-2032)
- 3.2.2 Global RNA-Targeted Small Molecules Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global RNA-Targeted Small Molecules Market Size Forecasted by Application (2027-2032)
- 3.3 Global RNA-Targeted Small Molecules Market Size by Regions
- 3.3.1 North America RNA-Targeted Small Molecules Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe RNA-Targeted Small Molecules Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific RNA-Targeted Small Molecules Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America RNA-Targeted Small Molecules Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa RNA-Targeted Small Molecules Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 RNA-Targeted Small Molecules Industry Trends
- 4.2 RNA-Targeted Small Molecules Industry Drivers
- 4.3 RNA-Targeted Small Molecules Industry Opportunities and Challenges
- 4.4 RNA-Targeted Small Molecules Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by RNA-Targeted Small Molecules Revenue (2021-2026)
- 5.2 Global RNA-Targeted Small Molecules Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global RNA-Targeted Small Molecules Key Company Headquarters & Area Served
- 5.4 Global RNA-Targeted Small Molecules Company, Product Type & Application
- 5.5 Global RNA-Targeted Small Molecules Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global RNA-Targeted Small Molecules Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 RNA-Targeted Small Molecules Players Market Share by Revenue in 2025
- 5.6.3 2025 RNA-Targeted Small Molecules Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Twentyeight-Seven Therapeutics
- 6.1.1 Twentyeight-Seven Therapeutics Company Information
- 6.1.2 Twentyeight-Seven Therapeutics Business Overview
- 6.1.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 6.1.5 Twentyeight-Seven Therapeutics Recent Developments
- 6.2 STORM Therapeutics
- 6.2.1 STORM Therapeutics Company Information
- 6.2.2 STORM Therapeutics Business Overview
- 6.2.3 STORM Therapeutics RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 STORM Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 6.2.5 STORM Therapeutics Recent Developments
- 6.3 Skyhawk Therapeutics
- 6.3.1 Skyhawk Therapeutics Company Information
- 6.3.2 Skyhawk Therapeutics Business Overview
- 6.3.3 Skyhawk Therapeutics RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Skyhawk Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 6.3.5 Skyhawk Therapeutics Recent Developments
- 6.4 Ribometrix
- 6.4.1 Ribometrix Company Information
- 6.4.2 Ribometrix Business Overview
- 6.4.3 Ribometrix RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Ribometrix RNA-Targeted Small Molecules Product Portfolio
- 6.4.5 Ribometrix Recent Developments
- 6.5 H3 Biomedicine
- 6.5.1 H3 Biomedicine Company Information
- 6.5.2 H3 Biomedicine Business Overview
- 6.5.3 H3 Biomedicine RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 H3 Biomedicine RNA-Targeted Small Molecules Product Portfolio
- 6.5.5 H3 Biomedicine Recent Developments
- 6.6 Gotham Therapeutics
- 6.6.1 Gotham Therapeutics Company Information
- 6.6.2 Gotham Therapeutics Business Overview
- 6.6.3 Gotham Therapeutics RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Gotham Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 6.6.5 Gotham Therapeutics Recent Developments
- 6.7 Expansion Therapeutics
- 6.7.1 Expansion Therapeutics Company Information
- 6.7.2 Expansion Therapeutics Business Overview
- 6.7.3 Expansion Therapeutics RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Expansion Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 6.7.5 Expansion Therapeutics Recent Developments
- 6.8 Epics Therapeutics
- 6.8.1 Epics Therapeutics Company Information
- 6.8.2 Epics Therapeutics Business Overview
- 6.8.3 Epics Therapeutics RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Epics Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 6.8.5 Epics Therapeutics Recent Developments
- 6.9 Arrakis Pharmaceuticals
- 6.9.1 Arrakis Pharmaceuticals Company Information
- 6.9.2 Arrakis Pharmaceuticals Business Overview
- 6.9.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecules Product Portfolio
- 6.9.5 Arrakis Pharmaceuticals Recent Developments
- 6.10 Anima Biotech Inc.
- 6.10.1 Anima Biotech Inc. Company Information
- 6.10.2 Anima Biotech Inc. Business Overview
- 6.10.3 Anima Biotech Inc. RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Anima Biotech Inc. RNA-Targeted Small Molecules Product Portfolio
- 6.10.5 Anima Biotech Inc. Recent Developments
- 6.11 Accent Therapeutics
- 6.11.1 Accent Therapeutics Company Information
- 6.11.2 Accent Therapeutics Business Overview
- 6.11.3 Accent Therapeutics RNA-Targeted Small Molecules Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Accent Therapeutics RNA-Targeted Small Molecules Product Portfolio
- 6.11.5 Accent Therapeutics Recent Developments
7 North America
- 7.1 North America RNA-Targeted Small Molecules Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 7.3 North America RNA-Targeted Small Molecules Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe RNA-Targeted Small Molecules Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 8.3 Europe RNA-Targeted Small Molecules Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific RNA-Targeted Small Molecules Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 9.3 Asia-Pacific RNA-Targeted Small Molecules Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America RNA-Targeted Small Molecules Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 10.3 South America RNA-Targeted Small Molecules Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa RNA-Targeted Small Molecules Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa RNA-Targeted Small Molecules Market Size by Country (2021-2026)
- 11.3 Middle East & Africa RNA-Targeted Small Molecules Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst